Therapy Areas: Oncology
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
10 July 2026 - Accord BioPharma, the US specialty division of India-based Intas Pharmaceuticals Ltd, focused on the development of oncology, immunology, and central nervous system (CNS) therapies, ann...
BiBBInstruments signs first European distribution deal for EndoDrill GI with Palex Spain
10 July 2026 - Swedish cancer diagnostics company BiBBInstruments AB (Spotlight Stock Market: BIBB) said on Thursday it has signed its first European commercial distribution agreement for its powered ...
Northwest Biotherapeutics presents updated DCVax-L Phase III trial survival data for glioblastoma
9 July 2026 - Northwest Biotherapeutics (OTCQB:NWBO)(NWBio), a biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, announced on Wednesday that the company�...
HanchorBio plans combination research with late-stage cancer drug resistance specialist InxMed
9 July 2026 - Taiwan-listed clinical-stage biotech HanchorBio Inc (TWSE:7827) announced on Wednesday that it is looking to broaden the development path for HCB101, its lead oncology asset, through a n...
GE HealthCare and Mayo Clinic launch prostate cancer theranostics research study
8 July 2026 - Healthcare solutions provider GE HealthCare Technologies Inc (NASDAQ: GEHC) and non-profit organisation Mayo Clinic announced on Wednesday the launch of the MI-BET (Molecular Imaging Bio...
Physiomics secures new contracts worth over GBP200,000
8 July 2026 - Physiomics plc (AIM: PYC), a mathematical modelling, data science and biostatistics company, declared on Wednesday that it has secured multiple contract awards with a combined estimated ...